KIYATEC PLACES 2ND AT REDEFINING EARLY STAGE INVESTMENTS (RESI) BOSTON
The conference showcased 30 of the most innovative life science technology companies and winners were chosen by investors, researchers and executives vote in RESI cash.
BOSTON, MA | September 16, 2015 – KIYATEC Inc. is pleased to announce that our RESI Conference poster entitled “The Business of Accurately Predicting Drug Response of Cancer Therapeutics” placed 2nd at the RESI Conference at the Westin Copley Place in Boston. The field of 30 presenting companies covered a broad array of life science technologies and each conference participant was given RESI cash with which they voted on their favorite technology company. KIYATEC’s ex vivo 3D cell culture platform is being used by numerous pharmaceutical and biotech companies to predict patient drug response using primary tumors cultured in a more clinically relevant in vitro screening approach. The platform is also being used to build out a robust clinical development pipeline to predict patient drug response.
• 3D cell culture techniques enable creation of clinically relevant in vitro tumor models.
• Ex Vivo 3D (EV3D) assay platform enables development of a broad range of cancer diagnostics.
• Complex co-culture models can be created to investigate immuno-oncology (IO) drug response.
• KIYATEC is expanding our clinical development pipeline in 2016 to begin clinical trials in ovarian, breast, GBM and lung cancers.
Current genomic technologies used in precision cancer care are proving to be less effective than initially touted. The reason for their lower effectiveness is that the presence of genomic alterations often does not correlate with results in the clinic. The current paradigm of basing clinical therapy decisions upon genetic mutation status fails to address the key problem in the field of oncology: patient response.
To address this problem, KIYATEC has developed clinically relevant in vitro assay systems that incorporate patient-derived tumor tissues. Our approach enables researchers and eventually, clinicians, to more effectively predict drug response in real-time in order to enhance preclinical drug candidate selection, clinical trial decision making (such as supporting adaptive trial designs) and clinical treatment regimens.
KIYATEC is now tackling drug development issues across a broad array of cancers including ovarian, breast, lung, GBM and pancreatic. Our assay platforms have been shown to be significantly more predictive than standard 2D cell culture techniques and when integrated upfront with traditional PDX models, can greatly enhance efficiency and lower costs. We are rapidly expanding our clinical development pipeline and plan on beginning pivotal trials in ovarian and breast cancers in 2016.